ClinicalTrials.gg
Active, not recruitingNCT04421573Updated Jul 14, 2026

Cervical Plexus Hydrodissection With D5W for PTSD

An interventional study of BCPHD with D5W and Waiting period with usual care in PTSD, sponsored by Dr. Dean Reeves Clinic. Active, not recruiting at 4 sites in United States. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Dr. Dean Reeves Clinic · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Planned enrollment
1,172nd of 1,491
24 · median 65
Started
2023
with 96 others
No phase
1,012 of 1,664
234 open now
Primary completion
2027-10
later than 236 of 402 live
Registered
1,040th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,172nd largest by planned enrollment of the 1,491 interventional ones that give a count, is one of 97 that started in 2023, is one of 1,012 with no phase, reaches primary completion later than 236 of the 402 other live ones, and was the 1,040th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 19 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with a delayed/usual treatment control.

Read the detailed description

PTSD is a well-recognized debilitating mental health condition associated with previous trauma exposure. It is part of the DSM-5 Trauma and Stressor related disorders category. Treatments for PTSD normally involve a multi-disciplinary approach. First-line treatments include psychotherapy and serotonergic reuptake inhibitors. Many patients fail pharmacotherapy and psychotherapy. Unilateral stellate ganglion block performed favorably for treatment of PTSD in a recent RCT, based upon an expectation that the cervical sympathetic system is neuropathically upregulated in PTSD. However, inclusion of lidocaine requires the presence of an emergency response team due to the potential for inadvertent intravascular injection with generalized seizures or hypotension, and inadvertent laryngeal or phrenic nerve block. Perineural injection of peripheral nerves, plexi, or sympathetic ganglia with dextrose 5% in water (D5W), has performed well empirically in the treatment of post-traumatic stress disorder. No lidocaine is utilized, which allows for avoidance of lidocaine toxicity risk, or any risk of nerve block. Because of that, bilateral procedures are feasible, and these procedures can be performed in any outpatient office with ultrasound availability, as emergency team backup is not necessary, making the procedure readily accessible. A cumulative benefit has been observed, as well. The effects of BHDCP with D5W as a stand-alone treatment for PTSD has not been formally evaluated. This small study is designed as a feasibility study with study acceptance rate, protocol adherence, and satisfaction as primary outcomes. Secondary outcomes will include short term and long-term effects of BHDCP with D5W on the Post Traumatic Stress Disorder Check List for Civilians (PCL-C), The primary hypotheses are that the acceptance rate and protocol adherence will both exceed 80%, and satisfaction will be 6/10 or higher on a 0-10 satisfaction scale. A study size of 24 is planned, based on power analysis.

03

Conditions studied

  • PTSD

Keywords

  • Dextrose
  • Hydrodissection
  • Cervical Plexus
04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Not involved in another study of PTSD treatment
  • Reliable transportation
  • Comfortable with computers
  • Tried 2 or more medications for treatment of PTSD symptoms
  • Tried 2 or more non-medication treatments for PTSD symptom
  • No known life-threatening illness
  • Not taking daily narcotics
  • Not having 3or more alcoholic drinks on an average day
  • No active suicidal plans
  • No major surgery plans
  • No major life stress that might interfere with completing study
  • Symptoms for more than 1 year
  • Not planning to move for next 18 months.
  • Living within an hour of Portlland, OR, Madison, WI, or Lexington, KY
  • Wiling to provide 2 email and 2 phone contact methods
  • Willing to answer questions on multiple occasions over the course of a year.
  • Willing to be assigned to 3 months of usual care treatment
  • No diagnosis of schizophrenia, Borderline Personality Disorder, or Bipolar Disorder.
  • No severe needle phobia
  • Chronic pain ≤ 5/10
  • PCL-C score ≥ 50

Exclusion Criteria: None separate from inclusion criteria

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    BCPHD-D5W with usual care

    Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks. All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.

    Procedure: BCPHD with D5W

  • Active comparator
    Waiting period with usual care

    All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.

    Procedure: Waiting period with usual care

Interventions

  • ProcedureBCPHD with D5W

    D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.

  • ProcedureWaiting period with usual care

    Same as previous group description

06

What researchers measure

Primary outcomes

  1. Consent rate

    Percentage consent rate for qualifying participants

    Time frame: 3 months

  2. Data Capture rate

    Percentage data capture

    Time frame: 3 months

  3. Satisfaction rating

    Satisfaction with treatment outcome as measured by a 0-10 Numerical Rating Scale (NRS)

    Time frame: 3 months

Secondary outcomes

  1. PCL-C Score

    Improvement (reduction) in PTSD check list for civilians

    Time frame: 3 months

  2. HADS scale

    Improvement in the Hospital Anxiety and Depression Scale

    Time frame: 3 months

  3. EuroQOL 0-100

    0-100 rating of quality of life

    Time frame: 3 months

  4. Qualitative interview

    Qualitative interview

    Time frame: Nine to twelve months after receiving first D5W treatment for PTSD

07

Study locations

4 sites
  • Danesh Mazloomdoost
    Lexington, Kentucky 40509, United States
  • Paul W. Johnson, D.O., Clinic.
    Portland, Oregon 87213, United States
  • NW Regen
    Tigard, Oregon 97224, United States
  • Eric Phillippi M.D. Clinic
    Madison, Wisconsin 53719, United States
08

References and documents

Publications

  • Rae Olmsted KL, Bartoszek M, Mulvaney S, McLean B, Turabi A, Young R, Kim E, Vandermaas-Peeler R, Morgan JK, Constantinescu O, Kane S, Nguyen C, Hirsch S, Munoz B, Wallace D, Croxford J, Lynch JH, White R, Walters BB. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Feb 1;77(2):130-138. doi: 10.1001/jamapsychiatry.2019.3474. PubMed 31693083 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 50 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 9, 2020
StartActual
Jul 10, 2023
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04421573
Lead sponsor
Dr. Dean Reeves Clinic
Collaborators
Paul Johnson, D.O., Eric Phillippi, M.D., Ryan Wood, N.D., Danesh Mazloomdoost
Responsible party
Dr. Dean Reeves (Principal Investigator, Dr. Dean Reeves Clinic) — Principal investigator
First posted
Jun 9, 2020
Start date
Jul 10, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Kenneth D Reeves, M.D.
principal investigator · Dr. Dean Reeves Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion